-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

Benzinga·08/19/2026 10:06:37
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.